On This Page |
COVID-19 Solutions | New Products | Latest News | Coronavirus Research Webinars | COVID-19 Resources |
Our Best-in-Class COVID-19 Solutions
Bio-Rad provides a wide range of products for use in the support of COVID-19 diagnostic screening, confirmation of test results, surveillance, and therapy/vaccine research and development. From molecular testing using real-time PCR or Droplet Digital PCR, to immunology assays, our wide range of solutions provide best in class sensitivity and accuracy.
Our COVID-19 diagnostic kits support the detection of the Omicron variant.
These pages list our product offerings in these areas. Some products have limited regional availability. If you have a specific question about coronavirus solutions, please contact your local sales office or representative. As we adhere to shelter-in-place guidelines worldwide, Bio-Rad continues to process orders and offer customer service and technical support.
From diagnostic solutions utilizing the most advanced Molecular and Immunology technologies to the basic research tools essential for the development of vaccines and therapies, our wide range of solutions provide best in class sensitivity and accuracy.
For COVID-19 testing, we offer the sensitive SARS-CoV-2 Droplet Digital PCR (ddPCR) Kit which is optimized for low viral load specimens and incorporates SARS-CoV-2 Standards for process monitoring from sample extraction.
For serological testing, we offer the Platelia SARS-CoV-2 Total Ab Assay, a single-test serological solution detecting the IgA, IgG and IgM responses, as well as VIROTROL SARS-CoV and local Bio-Rad sales office or representative. contact a Bio-Rad sales specialist.
Antibody Detection
COVID-19 Surveillance
Vaccine and Therapeutic R&D
New Products
-
PREvalence ddPCR SARS-CoV-2 Wastewater Quantification Kit
The new PREvalence ddPCR SARS-CoV-2 Wastewater Quantification Kit includes assay, controls, and supermix to detect SARS-CoV-2 virus in wastewater (sewage).
-
Reliance SARS-CoV-2 RT-PCR Assay Kits
The Reliance SARS-CoV-2 Kit includes assay, controls, and supermix to detect virus in clinical samples.
Chelex 100 Resin and InstaGene Matrix
Chelex 100 Resin and InstaGene Matrix can be used to develop rapid COVID-19 detection workflows that do not rely on RNA extraction kits.
-
PREvalence ddPCR SARS-CoV-2 Wastewater Quantification Kit
The new PREvalence ddPCR SARS-CoV-2 Wastewater Quantification Kit includes assay, controls, and supermix to detect SARS-CoV-2 virus in wastewater (sewage).
Chelex 100 Resin and InstaGene Matrix
Chelex 100 Resin and InstaGene Matrix can be used to develop rapid COVID-19 detection workflows that do not rely on RNA extraction kits.
Latest News
COVID-19 Updates from Bio-Rad
Bio-Rad COVID-19 diagnostic kits support detection of the Omicron variant. Learn More »
We are helping customers, colleagues, and the global community during this health crisis. Learn How »
-
02/12/2021
Bio-Rad’s Multi-Target Reliance SARS-CoV-2/FluA/FluB RT-PCR and Reliance SARS-CoV-2 RT-PCR Assay Kits Granted FDA Emergency Use Authorization -
06/18/2020
Bio-Rad Products Provide Support in the Fight against COVID-19 -
05/18/2020
Bio-Rad’s CFX96 Dx Real-Time PCR System is Listed with the U.S. Food and Drug Administration (FDA) for IVD Testing and May Be Used for COVID-19 Diagnosis. -
05/04/2020
Bio-Rad Receives FDA Emergency Use Authorization for Droplet Digital PCR SARS-CoV-2 Test Kit -
04/30/2020
Bio-Rad's SARS-CoV-2 (COVID-19) Serology Test Granted FDA Emergency Use Authorization, the First Total Antibody Test to Receive EUA from the FDA -
04/21/2020
Bio-Rad Begins Shipping SARS-COV-2 (COVID-19) Antibody Test That Offers More Than 99 Percent Specificity and 98 Percent Sensitivity -
04/07/2020
Bio-Rad Announces the Launch of a Serology Assay to Detect Coronavirus (COVID-19) Antibodies -
03/19/2020
New Studies Find Bio-Rad’s QX200 Droplet Digital PCR System Can Detect COVID-19 with Greater Sensitivity and Precision than Other Existing Molecular Tests -
03/18/2020
COVID-19 Update: Doing Our Part to Help Customers, Colleagues, and the Global Community During this Health Crisis -
03/18/2020
Bio-Rad Partners with Testing Labs Worldwide to Support COVID-19 Testing -
03/12/2020
Bio-Rad's Exact Diagnostics Launches SARS CoV-2 Standards for COVID-19 Testing.
Coronavirus Research Webinars
Upcoming Webinars
How to Develop a New Multiplex SARS‑CoV‑2 Variant Neutralizing Antibody Assay in a Day
Wednesday, June 15 at 9:00 AM PT and
Tuesday, June 21 at 8:30 PM PT
In this webinar, we will discuss the utilization of Bio‑Plex Pro Human SARS‑CoV‑2 Neutralization Custom Assay Developer Kit to efficiently develop new variant assays for the detection and determination of percentage inhibition of severe acute respiratory syndrome coronavirus 2 (SARS‑CoV‑2) neutralizing antibodies with affinity to SARS‑CoV‑2 variants.
You will learn about:
- Competitive multiplex immunoassay technology (format) in SARS‑CoV‑2 neutralizing antibody assay development
- Conjugating a SARS‑CoV‑2 variant antigen to a magnetic bead
- Developing a SARS‑CoV‑2 neutralizing antibody assay using Bio‑Plex SARS‑CoV‑2 Neutralization Antibody Custom Assay Developer Kit
- Determination of percent inhibition of SARS‑CoV‑2 neutralizing antibodies
Past Webinars
Immunological Response Factors to SARS‑CoV‑2 in Acquired Immunity
Tuesday, February 9 at 9:00AM PDT
In this webinar, we will be discussing the immune response to SARS‑CoV2, both in the context of natural exposure to the virus as well as induced immunity from vaccination. We will also investigate the relationship between symptom severity and the longevity of acquired immunity.
You will learn about:
- SARS‑CoV‑2 virion and ACE2 binding
- Initiation of the adaptive response
- T‑ and B‑lymphocyte maturity
- B‑lymphocyte conversion to memory and plasma cells
- Factors that affect the duration of acquired immunity
The Role of Aberrant Cytokine Activity in the Host Immune Response to COVID‑19
In this webinar, we will be discussing early research and nascent hypotheses regarding the pathophysiology of SARS‑CoV‑2 induced COVID-19 disease by evaluating cytokine and chemokine profiles, the role of chronic inflammation in comorbidities, and the arc of immune resolution of historical virulent pathogens, such as SARS and MERS.
Featured Article"Aberrant Cytokine Activity in the Host Immune Response to COVID‑19 Leads to Cytokine Release Syndrome"
Discover why the potential link between cytokine release syndrome (CRS) and COVID‑19‑related deaths warrants further investigation.
Real-Time PCR in Infectious Disease
In this webinar, learn more about:
- Characterizing COVID-19 using qPCR
- Accurately select your internal control
- Exploring 1-step v. 2-step in sample preparation
Live Expert Panel Discussion on the Relevance of COVID-19 Testing with Droplet Digital PCR
This webinar will discuss:
- Comparison of ddPCR to RT-PCR technologies
- Performance data from validation studies
- Case studies with hospital network
- The next wave of SARS-CoV-2 assays for vaccine development and surveillance
- Pharma needs for vaccine development
Using Bio-Plex Multiplex Immunoassays to Monitor T Cell Response to Anti‑PD1 Therapy
In this webinar you learn how to:
- Quickly monitor 20 cytokine profiles to assess patient response to immunotherapy
- Confidently evaluate safety profiles associated with biologics
- Measure cytokine overproduction associated with cytokine release syndrome
- Perform powerful analysis with multitimepoint, multipatient, and multidose measurements all on one 96-well plate
On-Demand Expert Panel Discussion on COVID-19 with Droplet Digital PCR and Antibody Testing
This webinar provides an overview of the approaches that Bio-Rad is taking in the battle against COVID‑19:
- Detection and diagnosis with Droplet Digital PCR
- Confirming with ddPCR testing to determine viral load and post-infection clearance
- Surveillance and diagnosis with serology testing to ensure adequate immune response and immunity
5th Droplet Digital PCR (ddPCR) Asia Pacific Symposium 2020
Learn from our panel of experts as they discuss how one of the most exciting technologies in biomedical science — Droplet Digital PCR — is revolutionizing nucleic acid detection and quantitation in the following topics:
- COVID-19 detection — detection of SARS-CoV-2 to increase confidence and reduce false negative test results
- Cell and Gene therapies — accelerating the development of new generation of therapies
- Liquid biopsy — rapid implementation of precise, personalised assays allowing clinicians to closely monitor patient progress and tailor treatment with confidence
Coronavirus Outbreak: The Singapore StoryThe Development of a Locally Made Diagnostic Kit to Combat the COVID-19 Pandemic
Learn how Bio-Rad helped the Singapore Agency for Science, Technology, and Research (A*STAR) develop their SARS-CoV-2 test kit for use in hospitals across Singapore.
COVID-19 Resources
2019-20 Coronavirus Pandemic (COVID-19; 2019-nCoV)
The novel coronavirus identified as the causative agent of pneumonia cases first detected in Wuhan City, China in December, 2019, was officially designated as SARS-CoV-2. On March 11, 2020, WHO declared COVID-19 a global pandemic. For the latest information on the Novel Coronavirus COVID-19 / 2019-nCoV pandemic, visit the World Health Organization website:
WHO.int > Emergencies > Diseases > Coronavirus disease 2019
The US Centers for Disease Control and Prevention provides valuable information for US and global citizens. See the CDC website for the 2019 Novel Coronavirus Situation Summary, guidance for travelers, information for healthcare and public health professionals, guidance for laboratory professionals, background information, and the latest news:
CDC.gov > 2019 Novel Coronavirus
Although there are no clinical diagnostics for coronavirus 2019-nCoV currently approved by the US Food & Drug Administration (FDA), on February 4th, 2020, the FDA issued an Emergency Use Authorization to temporarily expand the use of RT-PCR assays for the identification of 2019-nCoV. For updates, see the US Food & Drug Administration website:
FDA.gov > Medical Countermeasures Initiative (MCMi) > Novel Coronavirus (2019-nCoV)
FDA.gov > Medical Countermeasures Initiative (MCMi) > Emergency Use Authorization